588 related articles for article (PubMed ID: 17362051)
21. Long term safety of etanercept in elderly subjects with rheumatic diseases.
Fleischmann R; Baumgartner SW; Weisman MH; Liu T; White B; Peloso P
Ann Rheum Dis; 2006 Mar; 65(3):379-84. PubMed ID: 16150792
[TBL] [Abstract][Full Text] [Related]
22. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
Elkayam O; Caspi D; Reitblatt T; Charboneau D; Rubins JB
Semin Arthritis Rheum; 2004 Feb; 33(4):283-8. PubMed ID: 14978666
[TBL] [Abstract][Full Text] [Related]
23. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
[TBL] [Abstract][Full Text] [Related]
24. Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.
García-Lagunar MH; Gutiérrez-Cívicos MR; García-Simón MS; Conesa-Zamora P; Jimenez-Santos E; Cano-Vivar P; García-Márquez A; Muñoz-García I; Viney AC
Ann Pharmacother; 2017 May; 51(5):388-393. PubMed ID: 27920336
[TBL] [Abstract][Full Text] [Related]
25. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.
Conti F; Ceccarelli F; Marocchi E; Magrini L; Spinelli FR; Spadaro A; Scrivo R; Valesini G
Ann Rheum Dis; 2007 Oct; 66(10):1393-7. PubMed ID: 17613555
[TBL] [Abstract][Full Text] [Related]
26. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
[TBL] [Abstract][Full Text] [Related]
27. [Pharmaceutical care of patients with rheumatoid and psoriatic arthritis receiving etanercept].
Romero Crespo I; Antón Torres R; Borrás Blasco J; Navarro Ruiz A
Farm Hosp; 2005; 29(3):171-6. PubMed ID: 16013943
[TBL] [Abstract][Full Text] [Related]
28. Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides.
Braun J; van der Heijde D
Expert Opin Investig Drugs; 2003 Jul; 12(7):1097-109. PubMed ID: 12831346
[TBL] [Abstract][Full Text] [Related]
29. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France.
Saint Marcoux B; De Bandt M;
Joint Bone Spine; 2006 Dec; 73(6):710-3. PubMed ID: 17127088
[TBL] [Abstract][Full Text] [Related]
30. Repeated tuberculin skin testing following therapy with TNF-alpha inhibitors.
Fuchs I; Avnon L; Freud T; Abu-Shakra M
Clin Rheumatol; 2009 Feb; 28(2):167-72. PubMed ID: 18795393
[TBL] [Abstract][Full Text] [Related]
31. Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice.
Fabbroni M; Cantarini L; Caso F; Costa L; Pagano VA; Frediani B; Manganelli S; Galeazzi M
Mediators Inflamm; 2014; 2014():862969. PubMed ID: 25110401
[TBL] [Abstract][Full Text] [Related]
32. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.
Culy CR; Keating GM
Drugs; 2002; 62(17):2493-537. PubMed ID: 12421111
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review.
Romero-Maté A; García-Donoso C; Córdoba-Guijarro S
Am J Clin Dermatol; 2007; 8(3):143-55. PubMed ID: 17492843
[TBL] [Abstract][Full Text] [Related]
34. Safe re-administration of tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα therapy.
Suh YS; Kwok SK; Ju JH; Park KS; Park SH; Yoon CH
J Korean Med Sci; 2014 Jan; 29(1):38-42. PubMed ID: 24431903
[TBL] [Abstract][Full Text] [Related]
35. Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity.
Massarotti M; Marasini B
Int J Immunopathol Pharmacol; 2009; 22(2):547-9. PubMed ID: 19505409
[TBL] [Abstract][Full Text] [Related]
36. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
37. Etanercept: a review of its use in the management of ankylosing spondylitis and psoriatic arthritis.
Hoy SM; Scott LJ
Drugs; 2007; 67(17):2609-33. PubMed ID: 18034593
[TBL] [Abstract][Full Text] [Related]
38. The clinical application of etanercept in Chinese patients with rheumatic diseases.
Chou CT
Mod Rheumatol; 2006; 16(4):206-13. PubMed ID: 16906369
[TBL] [Abstract][Full Text] [Related]
39. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.
Toussirot É; Houvenagel É; Goëb V; Fouache D; Martin A; Le Dantec P; Dernis E; Wendling D; Ansemant T; Berthelot JM; Bader-Meunier B; Kantelip B;
Joint Bone Spine; 2012 Oct; 79(5):457-63. PubMed ID: 22088934
[TBL] [Abstract][Full Text] [Related]
40. Biological therapies in the spondyloarthritides--the current state.
Braun J; Sieper J
Rheumatology (Oxford); 2004 Sep; 43(9):1072-84. PubMed ID: 15187239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
